RAPID-19 [COVID-19]
Research type
Research Study
Full title
Rapid diagnostics, antibody testing and host response in children with Covid-19 (RAPID-19).
IRAS ID
282617
Contact name
Thomas Waterfield
Contact email
Sponsor organisation
Queen's University Belfast
Duration of Study in the UK
0 years, 8 months, 19 days
Research summary
Very little is known regarding the symptoms and signs of Covid-19 disease in children. In particular we do not know how many children are asymptomatic carriers of the SARS-CoV-2 virus and what the symptoms and signs of mild Covid-19 disease are. We also do not know why some, previously well, children develop severe disease. Research is required to understand the symptoms and signs of infection, the spectrum of disease and the host immune response in those with severe disease. Research to validate rapid diagnostic tests is also required.\n\nThe aims of this projects are to (i) validate the performance of a rapid molecular test for detecting SARS-CoV-2 in children (ii) follow healthy children through the seroconversion process to better understand the signs and symptoms of Covid-19 (iii) understand the immune response in children with severe disease. \n
REC name
London - Chelsea Research Ethics Committee
REC reference
20/HRA/1731
Date of REC Opinion
8 Apr 2020
REC opinion
Further Information Favourable Opinion